Metabolic Efficiency of Combined Pancreatic Islet and Lung Transplant for the Treatment of End-Stage Cystic Fibrosis

Inclusion criteria: * Patient with cystic fibrosis * Patient able to respect the protocol procedures * Patient with end-stage respiratory insufficiency indicating a lung transplant * Clinical history of cystic fibrosis related diabetes and/or insulin-dependent diabetes, with no residual insulin secretion (C-peptide \< 0,5 ng/mL) and/or no response to IV glucagon stimulation: \[peak stimulated C-peptide (T6min)/basal plasma C-peptide(T0)\] \< 2. The absence of insulin secretion will be verified 2 times before inclusion * Evolution of diabetes for over 3 years * Patient whose glycaemic control obtained with insulin therapy is not satisfactory and could significantly alter quality of life (HbA1c \> 7% and/or MAGE index \> 1,25). This situation is assessed by a diabetologist. * Social Security membership or benefit from Social Welfare * Patient who received the results of the medical evaluation required Non-inclusion criteria: * Patient with contra-indication for undergo a lung transplant * Patient with an indication of heart, liver or kidney transplantation * Patient for which poor therapeutic compliance is expected * Patient under oral antidiabetic drug * In women of childbearing potential: pregnancy test (urine and / or blood) positive, lactation, or unwilling to use effective contraception for the duration of the study until 3 months after the end . Men: procreation project during the study period up to 3 months after its end, or unwilling to use effective contraception patient. * Active infection, including hepatitis B, hepatitis C, HIV * Any history of malignancy within the past 5 years, with the exception of cutaneous basal cell carcinomas completely resected. The history of breast or melanoma cancers are an absolute contraindication * Alcoholic intoxication or drug addiction * Anemia (hemoglobin Hb \<10g / dL in women and Hb \<11 g / dL in men), lymphopenia (\<1000 / uL), neutropenia (\<1500 / uL) or thrombocytopenia (\<100,000 / uL). * Persistent elevated liver enzymes at baseline * Portal hypertension identified by oesophageal varice and/or hypersplenism (platelets \< 120 000 /mm3) or Child-Pugh score \> 6. * Use of a medical treatment under investigation within 4 weeks before inclusion * All medical situation assessed by an investigator which could interfere with the good management of the project * Patient restricted of freedom or unable to give his consent * Patient has been included in another study that could interfere with the results of the study * Contraindications to the use of experimental drugs (Cellcept®, prednisone, Prograf, prednisolone, methylprednisolone, and pancreatic islets)